<DOC>
	<DOCNO>NCT01730404</DOCNO>
	<brief_summary>Phase IIa study COPD patient aim evaluate safety , tolerability , pharmacodynamics ( effect biological marker inflammation induce sputum blood , pulmonary function ) pharmacokinetics CHF 6001 ( PDE4 inhibitor ) 28-days daily inhale dosing .</brief_summary>
	<brief_title>Safety , Tolerability Efficacy 28-day Inhaled CHF 6001 DPI COPD Patients</brief_title>
	<detailed_description />
	<criteria>1 . Written inform consent obtain prior studyrelated procedure . 2 . Male female age 40 70 year inclusive . 3 . Current past smoker least 10 pack/years 4 . BMI range 1835 Kg/m2 5 . GOLD Stage 2 3 COPD subject 6 . A history chronic bronchitis define chronic cough sputum production 7 . At screen , subject must able produce adequate induce sputum sample 8 . Female subject : postmenopausal woman least 12 month natural ( spontaneous ) amenorrhea , woman childbearing potential use two acceptable method contraception duration study follow three month Exclusion criterion : 1 . Female subject : pregnant lactate woman 2 . Past current history asthma 3 . History clinically significant hypotensive episode 4 . History symptom significant cardiovascular disease 5 . History symptom significant neurological disease 6 . Unstable concurrent disease 7 . An abnormal clinically significant 12lead ECG 8 . Clinically relevant abnormal laboratory value 9 . Use oral systemic corticosteroid oral and/or nebulised Beta2 agonist and/or antibiotic within 6 week precede screen visit 10 . Moderate severe hepatic impairment ( ChildPugh B C ) 11 . Intolerance/hypersensitivity contraindication treatment roflumilast , tiotropium bromide salbutamol excipients contain formulation use study 12 . Chronic use medication treatment lung disease like xanthine , antileukotrienes , systemic inhaled corticosteroid , long act beta2 agonist , roflumilast ( study drug ) cromoglycates 13 . Long term ( least 12 hour daily ) use oxygen therapy chronic hypoxemia . 14 . Having receive investigational medicinal drug within 30 day prior study entry 15 . Blood draw 250 mL within 45 day prior enrolment study . 16 . Known respiratory disorder COPD . 17 . History alcohol dependency , substance abuse 18 . Inability comply study Protocol reason .</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>